Aripiprazole (Abilify) Can Be Used Cautiously in Patients with Seizure History
Aripiprazole should be used cautiously in patients with a history of seizures or conditions that lower the seizure threshold, but it appears to carry one of the lowest seizure risks among antipsychotics. The FDA label explicitly states this caution, while emerging evidence suggests aripiprazole may actually have a more favorable seizure profile compared to other antipsychotics 1.
Key Clinical Evidence
FDA Labeling Guidance
The official Abilify prescribing information notes that in short-term placebo-controlled trials, seizures/convulsions occurred in only 0.1% (3/2,467) of adult patients and 0.1% (1/732) of pediatric patients treated with oral aripiprazole 1. The FDA recommends using aripiprazole cautiously in patients with a history of seizures or conditions that lower the seizure threshold, which may be more prevalent in populations 65 years or older 1.
Comparative Seizure Risk Data
Multiple large-scale studies demonstrate aripiprazole's relatively favorable seizure profile:
A 12-year Taiwanese population study of 288,397 antipsychotic users found aripiprazole had a marginally lower seizure risk compared to risperidone (adjusted HR = 0.41,95% CI 0.17-1.00, p=0.050) 2. In contrast, clozapine (HR=3.06), thioridazine (HR=2.90), and haloperidol (HR=2.34) showed significantly elevated risks.
A UK-based study examining patients with affective disorders and dementia found that amisulpride, aripiprazole, risperidone, or sulpiride as a group were not associated with increased seizure risk (adjusted OR 0.92,95% CI 0.48-1.75) in dementia patients, unlike other antipsychotic classes 3.
Animal studies in genetically epilepsy-prone rats showed aripiprazole was the only antipsychotic tested that demonstrated anticonvulsant effects after chronic administration, while clozapine, risperidone, olanzapine, and quetiapine increased seizure severity 4.
Clinical Decision Framework
When Aripiprazole Is Preferred
Aripiprazole should be considered the preferred antipsychotic option when:
- Patient has documented seizure history or epilepsy
- Patient has conditions lowering seizure threshold (brain injury, stroke, metabolic disturbances)
- Patient requires antipsychotic treatment but seizure risk must be minimized
- Patient is elderly (≥65 years) where seizure threshold may be lower 1
Monitoring Requirements
When prescribing aripiprazole to patients with seizure history:
- Start with lowest effective dose and titrate slowly
- Ensure patient is on appropriate antiepileptic medication if indicated
- Monitor for any breakthrough seizure activity
- Assess for conditions that further lower seizure threshold (dehydration, electrolyte imbalances, concurrent medications)
- Consider EEG monitoring if clinically indicated
Antipsychotics to Avoid
Do NOT use in patients with seizure history:
- Clozapine (highest risk: 3-fold increased seizure risk) 2, 3
- Chlorpromazine and other low-potency first-generation antipsychotics (2.6-3.1-fold increased risk) 2, 3
- Haloperidol and high-potency first-generation antipsychotics (2.3-2.5-fold increased risk) 2, 3
Important Caveats
Context-Dependent Risk
The actual seizure risk depends on multiple interacting factors:
- Underlying neurological substrate (brain tumor, stroke, traumatic brain injury creates higher baseline risk) 5
- Concurrent antiepileptic medications (some like levetiracetam may cause behavioral issues requiring antipsychotic treatment) 5
- Dose and titration speed (rapid escalation increases risk) 6
- Metabolic stability (electrolyte disturbances, renal/hepatic dysfunction) 5
Pediatric Considerations
A Korean nationwide study found that pediatric patients on antipsychotics had increased seizure risk, with aripiprazole independently associated with seizures (though the study did not compare relative risks between agents) 7. Exercise heightened caution in pediatric populations, use lowest effective doses, and monitor closely.
Recent Pharmacovigilance Data
A 2025 FAERS database analysis found aripiprazole showed moderate seizure reporting signals (ROR025 = 2.05), lower than ziprasidone, quetiapine, clozapine, and olanzapine, but higher than risperidone, paliperidone, and lurasidone 8. The study identified a negative correlation between 5-HT1A/D2 receptor affinity ratio and seizure risk, suggesting a potential protective mechanism with aripiprazole's pharmacodynamic profile.
Bottom Line
Aripiprazole represents one of the safer antipsychotic choices for patients with seizure history, particularly when compared to clozapine and first-generation antipsychotics. While the FDA label appropriately recommends caution, the preponderance of evidence suggests aripiprazole may actually have anticonvulsant properties or at minimum a neutral effect on seizure threshold. Start low, titrate slowly, ensure adequate antiepileptic coverage if indicated, and monitor for breakthrough seizures.